These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 21488802)

  • 1. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
    Hanefeld M; Haffner SM; Menschikowski M; Koehler C; Temelkova-Kurktschiev T; Wildbrett J; Fischer S
    Diabetes Res Clin Pract; 2002 Mar; 55(3):221-7. PubMed ID: 11850098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.
    Laube H; Linn T; Heyen P
    Exp Clin Endocrinol Diabetes; 1998; 106(3):231-3. PubMed ID: 9710365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
    Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M
    Diabetes Obes Metab; 2003 Jan; 5(1):38-44. PubMed ID: 12542723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
    Inoue I; Takahashi K; Noji S; Awata T; Negishi K; Katayama S
    Diabetes Res Clin Pract; 1997 Jun; 36(3):143-51. PubMed ID: 9237780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes.
    Wagner H; Degerblad M; Thorell A; Nygren J; Ståhle A; Kuhl J; Brismar TB; Ohrvik J; Efendic S; Båvenholm PN
    Diabetes Care; 2006 Jul; 29(7):1471-7. PubMed ID: 16801564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study.
    Derosa G; Maffioli P; D'Angelo A; Fogari E; Bianchi L; Cicero AF
    J Diabetes Complications; 2011; 25(4):258-66. PubMed ID: 21367625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
    Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
    Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
    Meneilly GS; Ryan EA; Radziuk J; Lau DC; Yale JF; Morais J; Chiasson JL; Rabasa-Lhoret R; Maheux P; Tessier D; Wolever T; Josse RG; Elahi D
    Diabetes Care; 2000 Aug; 23(8):1162-7. PubMed ID: 10937515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose.
    Wohl P; Krusinová E; Hill M; Kratochvílová S; Zídková K; Kopecký J; Neskudla T; Pravenec M; Klementová M; Vrbíková J; Wohl P; Mlejnek P; Pelikánová T
    Eur J Endocrinol; 2010 Oct; 163(4):573-83. PubMed ID: 20630944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.
    López-Alvarenga JC; Aguilar-Salinas CA; Velasco-Perez ML; Arita-Melzer O; Guillen LE; Wong B; Brito G; Mercado V; Gómez-Pérez FJ; Rull-Rodrigo JA
    Diabetes Obes Metab; 1999 Jan; 1(1):29-35. PubMed ID: 11221809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Sakamoto N; Tajima N
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
    [No Abstract]   [Full Text] [Related]  

  • 18. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
    Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.